UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 825

Sortiert nach

ACG Clinical Guideline: Management of Crohn's Disease in Adults

The American journal of gastroenterology, 2018-04, Vol.113 (4), p.481-517

2018

Volltextzugriff (PDF)

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

The New England journal of medicine, 2019-09, Vol.381 (13), p.1215-1226

2019

Volltextzugriff (PDF)

Biomarkers of Inflammation in Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2015-10, Vol.149 (5), p.1275-1285.e2

Sands, Bruce E

2015

Volltextzugriff (PDF)

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Gastroenterology (New York, N.Y. 1943), 2021-04, Vol.160 (5), p.1570-1583

2021

Volltextzugriff (PDF)

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2019-09, Vol.381 (13), p.1201-1214

2019

Volltextzugriff (PDF)

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2017-05, Vol.376 (18), p.1723-1736

2017

Volltextzugriff (PDF)

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

Clinical gastroenterology and hepatology, 2019-07, Vol.17 (8), p.1541-1550

2019

Volltextzugriff (PDF)

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2013-08, Vol.369 (8), p.699-710

2013

Volltextzugriff (PDF)

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

The New England journal of medicine, 2013-08, Vol.369 (8), p.711-721

2013

Volltextzugriff (PDF)

Inflammatory bowel disease: past, present, and future

Journal of gastroenterology, 2007, Vol.42 (1), p.16-25

Sands, Bruce E

2007

Volltextzugriff (PDF)

Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial

Clinical gastroenterology and hepatology, 2022-03, Vol.20 (3), p.578-590.e4

2022

Volltextzugriff (PDF)

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2023-06, Vol.388 (26), p.2444-2455

2023

Volltextzugriff (PDF)

416a – Vedolizumab Shows Superior Efficacy Versus Adalimumab: Results of Varsity—The First Head-To-Head Study of Biologic Therapy for Moderate-To-Severe Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-81-S-81

2019

Volltextzugriff (PDF)

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

The New England journal of medicine, 2012-10, Vol.367 (16), p.1519-1528

2012

Volltextzugriff (PDF)

Converging Goals of Treatment of Inflammatory Bowel Disease From Clinical Trials and Practice

Gastroenterology (New York, N.Y. 1943), 2015, Vol.148 (1), p.37-51.e1

2015

Volltextzugriff (PDF)

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

Inflammatory bowel diseases, 2017-01, Vol.23 (1), p.97-106

2017

Volltextzugriff (PDF)

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium

The American journal of gastroenterology, 2016-08, Vol.111 (8), p.1147-1155

2016

Volltextzugriff (PDF)

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, Patients With Moderate to Severe Crohn's Disease: a Phase 2a Study

Gastroenterology (New York, N.Y. 1943), 2017-07, Vol.153 (1), p.77-86.e6

2017

Volltextzugriff (PDF)

Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity

Gastroenterology (New York, N.Y. 1943), 2013-11, Vol.145 (5), p.987-995

2013

Volltextzugriff (PDF)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

Gut, 2012-04, Vol.61 (4), p.535-542

2012

Volltextzugriff (PDF)

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease

Journal of Crohn's and colitis, 2020-01, Vol.14 (1), p.23-32

2020

Volltextzugriff (PDF)

Gastroenterology

Sands, Bruce E

1, 2014

Volltextzugriff (PDF)

From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation

Gastroenterology (New York, N.Y. 1943), 2004-05, Vol.126 (6), p.1518-1532

Sands, Bruce E

2004

Volltextzugriff (PDF)

Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study

The American journal of gastroenterology, 2020-05, Vol.115 (5), p.738-745

2020

Volltextzugriff (PDF)

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Journal of Crohn's and colitis, 2022-08, Vol.16 (8), p.1222-1234

2022

Volltextzugriff (PDF)

1 – 25 von 825

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(760)
Mit Volltextzugriff
(663)

Publikationsform

Artikel
(764)
Buchkapitel
(58)
Bücher
(2)
Berichte
(1)

Sprache

Englisch
(824)
Japanisch
(75)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

ACG Clinical Guideline: Management of Crohn's Disease in Adults

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Biomarkers of Inflammation in Inflammatory Bowel Disease

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

Inflammatory bowel disease: past, present, and future

Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

416a – Vedolizumab Shows Superior Efficacy Versus Adalimumab: Results of Varsity—The First Head-To-Head Study of Biologic Therapy for Moderate-To-Severe Ulcerative Colitis

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

Converging Goals of Treatment of Inflammatory Bowel Disease From Clinical Trials and Practice

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, Patients With Moderate to Severe Crohn's Disease: a Phase 2a Study

Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease

Gastroenterology

From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation

Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Suchergebnisse filtern